Company Overview

Cellectis S.A. is a French biotechnology company focused on developing gene-edited cell and gene therapies, primarily for oncology and severe diseases. The company operates within the biotechnology, genetic engineering, and immunotherapy industries, with a strategic emphasis on allogeneic CAR-T cell therapies created using proprietary gene-editing technologies. Cellectis is publicly traded in France and the United States and has historically positioned itself as one of the early developers of TALEN-based genome editing for therapeutic applications. Its principal revenue sources have included collaboration agreements, licensing arrangements, research funding, and milestone payments tied to strategic partnerships, rather than recurring commercial product sales.

The company’s core platform is based on Transcription Activator-Like Effector Nucleases (TALEN), which are used to engineer immune cells intended to target cancers while reducing risks associated with graft-versus-host disease. Cellectis evolved from a genome engineering research company founded in 1999 into a clinical-stage biotechnology enterprise pursuing off-the-shelf immunotherapies. Over time, it expanded its focus from broad genome engineering applications toward oncology-focused allogeneic CAR-T programs, while also maintaining capabilities in plant genome engineering through affiliated activities and historical investments.

Business Operations

Cellectis conducts operations through research, clinical development, manufacturing, and strategic collaboration activities centered on gene-edited cellular therapeutics. The company’s principal business units include its therapeutic development operations and manufacturing infrastructure supporting allogeneic CAR-T production. Its therapeutic candidates have targeted hematologic malignancies including acute lymphoblastic leukemia and non-Hodgkin lymphoma. Revenue generation has depended significantly on licensing and collaboration agreements with larger pharmaceutical and biotechnology companies, including historical collaborations involving Servier, Pfizer, and other research partners.

The company maintains internal genome editing capabilities built around its TALEN technology platform and related intellectual property portfolio. Cellectis also controls manufacturing and process development assets intended to support clinical-grade cell therapy production. Internationally, the company has operated through facilities in France and the United States, including research and manufacturing operations in the Paris region and New York. Subsidiaries and affiliated entities have included Cellectis, Inc. in the United States and historical relationships involving plant biotechnology operations associated with Calyxt, Inc., although the scope of those activities has evolved over time based on public filings and restructuring disclosures.

Strategic Position & Investments

Cellectis has focused strategically on developing off-the-shelf allogeneic CAR-T therapies intended to address scalability and manufacturing limitations associated with autologous cell therapies. Its growth initiatives have centered on advancing wholly owned clinical programs, expanding manufacturing capabilities, and leveraging partnerships to fund development. The company has invested heavily in proprietary gene-editing technologies and process engineering intended to enable standardized cell therapy products with reduced production timelines compared with patient-specific approaches.

Major strategic transactions and collaborations have included agreements with Servier and Pfizer related to immuno-oncology development programs. Cellectis has also pursued investment in automated manufacturing and translational research infrastructure to support clinical-stage development. The company remains active in emerging sectors involving genome editing, engineered immune cells, and next-generation oncology therapeutics. Public disclosures indicate continued prioritization of hematologic cancer indications and platform optimization, though timelines and program advancement remain dependent on clinical and regulatory outcomes.

Geographic Footprint

Cellectis is headquartered in Paris, France, and maintains operational activities in both Europe and North America. Its principal research and corporate functions are based in France, while U.S. operations have supported clinical development, manufacturing, and investor-facing activities. The company has maintained a presence in the biotechnology ecosystems of France and the United States, including facilities associated with translational medicine and cell therapy manufacturing.

The company’s strategic partnerships and investor base have provided international exposure beyond its core operating regions. Clinical and commercial collaboration activities have involved multinational pharmaceutical companies and regulatory engagement across multiple jurisdictions. Although Cellectis does not currently operate as a large-scale commercial pharmaceutical company, its technology platform and partnerships have given it influence within the global gene-editing and immunotherapy sectors.

Leadership & Governance

Cellectis was founded by André Choulika and has remained closely associated with its original scientific leadership. The company’s governance structure reflects its identity as a clinical-stage biotechnology enterprise emphasizing scientific innovation, intellectual property development, and strategic partnerships. Public statements and filings have consistently emphasized long-term investment in genome editing, manufacturing capability, and oncology-focused therapeutic development.

Key executives and leadership figures include:

• André Choulika – Co-Founder and Chief Executive Officer
• Mark Frattini – Chief Financial Officer
• Philippe Duchateau – Senior Executive Vice President, Chief Scientific Officer
• Damien Campagne – Chief Business Officer
• Karen Stierle – General Counsel

Company leadership has consistently articulated a strategy centered on advancing allogeneic CAR-T therapies through proprietary gene-editing technology, disciplined capital allocation, and partnership-driven development. Governance disclosures in public filings indicate oversight through a board structure consistent with French corporate governance requirements and U.S. public market reporting obligations.